183 related articles for article (PubMed ID: 10944947)
1. [Recent studies on anti-angiogenesis in cancer therapy].
Kishi K; Milas L; Hunter N; Sato M
Nihon Rinsho; 2000 Aug; 58(8):1747-62. PubMed ID: 10944947
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
[TBL] [Abstract][Full Text] [Related]
5. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
6. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
7. SU6668, a multitargeted angiogenesis inhibitor.
Hoekman K
Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
[TBL] [Abstract][Full Text] [Related]
8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
9. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
10. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy.
Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P
Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084
[No Abstract] [Full Text] [Related]
11. The clinical implications of angiogenesis in the treatment of cancer.
Aoun E; Taher A
J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis therapy in pancreatic carcinoma.
Saif MW
JOP; 2006 Mar; 7(2):163-73. PubMed ID: 16525200
[TBL] [Abstract][Full Text] [Related]
13. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.
Toomey DP; Manahan E; McKeown C; Rogers A; McMillan H; Geary M; Conlon KC; Murphy JF
Pancreas; 2010 Jul; 39(5):595-603. PubMed ID: 20118820
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in ovarian cancer.
Brown MR; Blanchette JO; Kohn EC
Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Dec; 14(6):901-18. PubMed ID: 11141340
[TBL] [Abstract][Full Text] [Related]
16. Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids.
Rose DP; Connolly JM
Nutr Cancer; 2000; 37(2):119-27. PubMed ID: 11142082
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
18. Combining radiotherapy and angiogenesis inhibitors: clinical trial design.
Citrin D; Ménard C; Camphausen K
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):15-25. PubMed ID: 16377411
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor as a target for antiangiogenic therapy.
Gordon MS
J Clin Oncol; 2000 Nov; 18(21 Suppl):45S-6S. PubMed ID: 11060326
[No Abstract] [Full Text] [Related]
20. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
